The acute and chronic pharmacokinetic oral fluid profile of oral cannabidiol (CBD) with and without low doses of delta-9-tetrahydrocannabinol (Δ9-THC) in healthy human volunteers
Journal of Analytical Toxicology · 2025
DOI: 10.1093/jat/bkaf102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Toxicology, 2025. Verfasst von Svante Vikingsson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Analytical Sciences, RTI International, Research Triangle Park, NC 27709, United States. Hauptthemen laut MEDLINE: Dronabinol, Cannabidiol, Saliva, Substance Abuse Detection. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Division of Workplace Programs, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration (SAMHSA) through the National….
Abstract (Originalsprache)
Δ9-tetrahydrocannabinol (Δ9-THC)-dominant cannabis use can cause impairment and risks to workplace safety, which makes the detection of Δ9-THC in oral fluid (OF) important for workplace drug testing. However, cannabidiol (CBD)-dominant cannabis sold as legal hemp products (≤0.3% Δ9-THC) often contain some Δ9-THC. In the present study, participants self-administered 1.5 mL medium-chain triglyceride (MCT) oil containing 100 mg CBD and either 0, 0.5, 1.0, 2.0, 2.8, or 3.7 mg Δ9-THC twice daily for 14 days (n = 10/Δ9-THC dose condition), followed by a 7-day washout period. OF CBD, 7-hydroxy-cannabidiol (7-OH-CBD), 7-carboxy-cannabidiol (7-COOH-CBD), Δ9-THC, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC), and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (Δ9-THC-COOH) were measured by LC-MS/MS (cutoff 0.025 ng/mL). Median CBD peaked at 2198 ng/mL 0.5 h after dosing, which likely reflects a high amount of direct oral cavity deposition, followed by a rapid decline. CBD pharmacokinetics were unaffected by the co-administration of Δ9-THC. CBD and Δ9-THC metabolite concentrations were low (<2 ng/mL), with some accumulation observed for 7-COOH-CBD with twice-daily exposure. After dosing with 100 mg CBD + 0.5 mg Δ9-THC, 1/10 participants had a positive OF test (≥2 ng/mL Δ9-THC) 1.5-6 h after a single acute dose. The rate of positive test results increased as Δ9-THC doses increased to 8/10 participants testing positive after acute doses of 100 mg CBD + 2.8 or 3.7 mg Δ9-THC. A consumer of hemp products might be unaware of the risk of a positive drug test as many products do not specify that they contain Δ9-THC. One positive sample was obtained at baseline, possibly due to direct oral cavity deposition of environmental contamination. Five samples in the CBD alone group, collected 0.5 h after dosing, were positive, likely due to minimal (0.02%–0.15%) conversion of CBD to Δ9-THC during analysis. Laboratories are advised to take action to identify specimens where OF Δ9-THC results could be influenced by these factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Analytical Sciences, RTI International, Research Triangle Park, NC 27709, United States.
- Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD 21224, United States.
- Division of Workplace Programs (DWP), Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD 20857, United States.
- Clinical Reference Laboratory, Lenexa, KS 66214, United States.
ORCID-Profile: Svante Vikingsson, C Austin Zamarripa, Ruth E Winecker
Förderung
- Division of Workplace Programs, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration (SAMHSA) through the National…
Zitieren
APA
Vikingsson, S., Zamarripa, C. A., Spindle, T. R., Klausner, M., Wolinsky, D., Cone, E. J., Winecker, R. E., Flegel, R. R., Davis, L. S., Hayes, E. D., Kuntz, D., & Vandrey, R. (2025). The acute and chronic pharmacokinetic oral fluid profile of oral cannabidiol (CBD) with and without low doses of delta-9-tetrahydrocannabinol (Δ9-THC) in healthy human volunteers. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkaf102
Vancouver
Vikingsson S, Zamarripa CA, Spindle TR, Klausner M, Wolinsky D, Cone EJ, et al. The acute and chronic pharmacokinetic oral fluid profile of oral cannabidiol (CBD) with and without low doses of delta-9-tetrahydrocannabinol (Δ9-THC) in healthy human volunteers. Journal of Analytical Toxicology. 2025. doi:10.1093/jat/bkaf102
BibTeX
@article{Vikingsson2025,
author = {Vikingsson, Svante and Zamarripa, C Austin and Spindle, Tory R and Klausner, McKenna and Wolinsky, David and Cone, Edward J and Winecker, Ruth E and Flegel, Ronald R and Davis, Lisa S and Hayes, Eugene D and Kuntz, David and Vandrey, Ryan},
title = {The acute and chronic pharmacokinetic oral fluid profile of oral cannabidiol (CBD) with and without low doses of delta-9-tetrahydrocannabinol (Δ9-THC) in healthy human volunteers},
journal = {Journal of Analytical Toxicology},
year = {2025},
doi = {10.1093/jat/bkaf102}
}
EUVIMED